Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022007921 - TRIAZINE COMPOUND AND COMPOSITION AND USE THEREOF

Publication Number WO/2022/007921
Publication Date 13.01.2022
International Application No. PCT/CN2021/105385
International Filing Date 09.07.2021
IPC
C07D 487/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/53 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
53having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 37/02 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
Applicants
  • 北京范恩柯尔生物科技有限公司 BEIJING FINDCURE BIOSCIENCES, LTD. [CN]/[CN]
Inventors
  • 习宁 XI, Ning
  • 许世民 XU, Shimin
  • 王婷瑾 WANG, Tingjin
Agents
  • 北京蕙识同联专利代理事务所(特殊普通合伙) HUIP PATENT ATTORNEYS
Priority Data
202010662669.210.07.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) TRIAZINE COMPOUND AND COMPOSITION AND USE THEREOF
(FR) COMPOSÉ TRIAZINE, COMPOSITION ET UTILISATION ASSOCIÉES
(ZH) 三嗪类化合物及其组合物和用途
Abstract
(EN) The present invention relates to the field of medicine, and specifically relates to a triazine compound as represented by formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, and use of the compound and the pharmaceutical composition thereof in the preparation of drugs for treating and/or preventing proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases, or other diseases in mammals. The compound provided by the present invention exhibits excellent inhibitory activity and kinase selectivity against a target kinase.
(FR) La présente invention se rapporte au domaine des produits pharmaceutiques, et concerne en particulier un composé triazine tel que représenté par la formule (I) ou un stéréoisomère, un tautomère, un oxyde d'azote, un solvate ou un sel pharmaceutiquement acceptable de celui-ci, une composition pharmaceutique contenant le composé, et l'utilisation du composé et de la composition pharmaceutique associée dans la préparation de médicaments pour le traitement et/ou la prévention de maladies prolifératives, de maladies auto-immunes, de maladies allergiques, de maladies inflammatoires, du rejet de greffe, de cancers, de maladies infectieuses virales ou d'autres maladies chez des mammifères. Le composé selon la présente invention a une excellente activité inhibitrice et une excellente sélectivité vis-à-vis d'une kinase cible.
(ZH) 本发明属于药物领域,具体涉及式(I)所示的三嗪类化合物、或其立体异构体、互变异构体、氮氧化物、溶剂化物、或药学上可接受的盐,和包含所述化合物的药物组合物以及使用所述化合物及其药物组合物在制备治疗和/或预防哺乳动物的增殖性疾病、自身免疫性疾病、过敏性疾病、炎性疾病、移植排斥、癌症、病毒感染性疾病或其他疾病的药物中的用途。本发明提供的化合物对目标激酶显示出优异的抑制活性和激酶选择性。
Latest bibliographic data on file with the International Bureau